Cargando…

The Clinical and Histopathological Feature of Renal Manifestation of TAFRO Syndrome

INTRODUCTION: Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome is a severe subtype of idiopathic multicentric Castleman’s disease, characterized by thrombocytopenia, anasarca, fever, reticulin myelofibrosis, and organomegaly. Renal complication of this...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizuno, Hiroki, Sawa, Naoki, Watanabe, Shun, Ikuma, Daisuke, Sekine, Akinari, Kawada, Masahiro, Yamanouchi, Masayuki, Hasegawa, Eiko, Suwabe, Tatsuya, Hoshino, Junichi, Takaichi, Kenmei, Kinowaki, Keiichi, Fujii, Takeshi, Ohashi, Kenichi, Nagata, Michio, Yamaguchi, Yutaka, Ubara, Yoshifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403508/
https://www.ncbi.nlm.nih.gov/pubmed/32775816
http://dx.doi.org/10.1016/j.ekir.2020.05.004
_version_ 1783566956184469504
author Mizuno, Hiroki
Sawa, Naoki
Watanabe, Shun
Ikuma, Daisuke
Sekine, Akinari
Kawada, Masahiro
Yamanouchi, Masayuki
Hasegawa, Eiko
Suwabe, Tatsuya
Hoshino, Junichi
Takaichi, Kenmei
Kinowaki, Keiichi
Fujii, Takeshi
Ohashi, Kenichi
Nagata, Michio
Yamaguchi, Yutaka
Ubara, Yoshifumi
author_facet Mizuno, Hiroki
Sawa, Naoki
Watanabe, Shun
Ikuma, Daisuke
Sekine, Akinari
Kawada, Masahiro
Yamanouchi, Masayuki
Hasegawa, Eiko
Suwabe, Tatsuya
Hoshino, Junichi
Takaichi, Kenmei
Kinowaki, Keiichi
Fujii, Takeshi
Ohashi, Kenichi
Nagata, Michio
Yamaguchi, Yutaka
Ubara, Yoshifumi
author_sort Mizuno, Hiroki
collection PubMed
description INTRODUCTION: Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome is a severe subtype of idiopathic multicentric Castleman’s disease, characterized by thrombocytopenia, anasarca, fever, reticulin myelofibrosis, and organomegaly. Renal complication of this disease can be life-threatening and sometimes requires hemodialysis, but it has not been elucidated in detail. METHODS: Case-series was designed to evaluate the renal histology of patients with TAFRO syndrome treated at our hospital. RESULTS: Seven patients were eligible to the criteria. All of them had severe diuretic-resistant anasarca and 6 of 7 had mild proteinuria (<1 g daily). On light microscopy, all patients showed glomerular endotheliopathy characterized by endothelial cell swelling and a double contour of the glomerular basement membrane with mesangiolysis or mesangial loosening. Immunofluorescent staining and electron microscopy did not detect immune deposits in any patient. Electron microscopy revealed endothelial cell swelling with diffuse expansion of the subendothelial space, loss of mesangial architecture, and loss of endothelial cell fenestrations. Treatment with glucocorticoids and molecular-targeting agents, including tocilizumab and rituximab, improved renal dysfunction and anasarca. In 4 of 7 patients with persistent thrombocytopenia, hemorrhagic events occurred despite platelet transfusion or thrombopoietin receptor antagonist therapy. CONCLUSION: Severe diuretic-resistant anasarca with mild proteinuria and severe glomerular endotheliopathy were common characteristics of renal dysfunction due to TAFRO syndrome. In addition, endothelial changes mediated via interleukin (IL)-6 and vascular endothelial growth factor (VEGF) that lead to vascular hyperpermeability and water leakage might contribute to anasarca, because molecular-targeting therapy directed against IL-6 or VEGF improved renal dysfunction and severe endothelial damage.
format Online
Article
Text
id pubmed-7403508
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-74035082020-08-06 The Clinical and Histopathological Feature of Renal Manifestation of TAFRO Syndrome Mizuno, Hiroki Sawa, Naoki Watanabe, Shun Ikuma, Daisuke Sekine, Akinari Kawada, Masahiro Yamanouchi, Masayuki Hasegawa, Eiko Suwabe, Tatsuya Hoshino, Junichi Takaichi, Kenmei Kinowaki, Keiichi Fujii, Takeshi Ohashi, Kenichi Nagata, Michio Yamaguchi, Yutaka Ubara, Yoshifumi Kidney Int Rep Clinical Research INTRODUCTION: Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome is a severe subtype of idiopathic multicentric Castleman’s disease, characterized by thrombocytopenia, anasarca, fever, reticulin myelofibrosis, and organomegaly. Renal complication of this disease can be life-threatening and sometimes requires hemodialysis, but it has not been elucidated in detail. METHODS: Case-series was designed to evaluate the renal histology of patients with TAFRO syndrome treated at our hospital. RESULTS: Seven patients were eligible to the criteria. All of them had severe diuretic-resistant anasarca and 6 of 7 had mild proteinuria (<1 g daily). On light microscopy, all patients showed glomerular endotheliopathy characterized by endothelial cell swelling and a double contour of the glomerular basement membrane with mesangiolysis or mesangial loosening. Immunofluorescent staining and electron microscopy did not detect immune deposits in any patient. Electron microscopy revealed endothelial cell swelling with diffuse expansion of the subendothelial space, loss of mesangial architecture, and loss of endothelial cell fenestrations. Treatment with glucocorticoids and molecular-targeting agents, including tocilizumab and rituximab, improved renal dysfunction and anasarca. In 4 of 7 patients with persistent thrombocytopenia, hemorrhagic events occurred despite platelet transfusion or thrombopoietin receptor antagonist therapy. CONCLUSION: Severe diuretic-resistant anasarca with mild proteinuria and severe glomerular endotheliopathy were common characteristics of renal dysfunction due to TAFRO syndrome. In addition, endothelial changes mediated via interleukin (IL)-6 and vascular endothelial growth factor (VEGF) that lead to vascular hyperpermeability and water leakage might contribute to anasarca, because molecular-targeting therapy directed against IL-6 or VEGF improved renal dysfunction and severe endothelial damage. Elsevier 2020-05-19 /pmc/articles/PMC7403508/ /pubmed/32775816 http://dx.doi.org/10.1016/j.ekir.2020.05.004 Text en © 2020 International Society of Nephrology. Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Clinical Research
Mizuno, Hiroki
Sawa, Naoki
Watanabe, Shun
Ikuma, Daisuke
Sekine, Akinari
Kawada, Masahiro
Yamanouchi, Masayuki
Hasegawa, Eiko
Suwabe, Tatsuya
Hoshino, Junichi
Takaichi, Kenmei
Kinowaki, Keiichi
Fujii, Takeshi
Ohashi, Kenichi
Nagata, Michio
Yamaguchi, Yutaka
Ubara, Yoshifumi
The Clinical and Histopathological Feature of Renal Manifestation of TAFRO Syndrome
title The Clinical and Histopathological Feature of Renal Manifestation of TAFRO Syndrome
title_full The Clinical and Histopathological Feature of Renal Manifestation of TAFRO Syndrome
title_fullStr The Clinical and Histopathological Feature of Renal Manifestation of TAFRO Syndrome
title_full_unstemmed The Clinical and Histopathological Feature of Renal Manifestation of TAFRO Syndrome
title_short The Clinical and Histopathological Feature of Renal Manifestation of TAFRO Syndrome
title_sort clinical and histopathological feature of renal manifestation of tafro syndrome
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403508/
https://www.ncbi.nlm.nih.gov/pubmed/32775816
http://dx.doi.org/10.1016/j.ekir.2020.05.004
work_keys_str_mv AT mizunohiroki theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT sawanaoki theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT watanabeshun theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT ikumadaisuke theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT sekineakinari theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT kawadamasahiro theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT yamanouchimasayuki theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT hasegawaeiko theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT suwabetatsuya theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT hoshinojunichi theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT takaichikenmei theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT kinowakikeiichi theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT fujiitakeshi theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT ohashikenichi theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT nagatamichio theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT yamaguchiyutaka theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT ubarayoshifumi theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT mizunohiroki clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT sawanaoki clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT watanabeshun clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT ikumadaisuke clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT sekineakinari clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT kawadamasahiro clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT yamanouchimasayuki clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT hasegawaeiko clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT suwabetatsuya clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT hoshinojunichi clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT takaichikenmei clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT kinowakikeiichi clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT fujiitakeshi clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT ohashikenichi clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT nagatamichio clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT yamaguchiyutaka clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome
AT ubarayoshifumi clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome